M. Bouma

发表

Stability and compatibility of the investigational polymer-conjugated platinum anticancer agent AP 5280 in infusion systems and its hemolytic potential

J. Reedijk, B. Nuijen, A. Bult, 2002, Anti-cancer drugs.

Pharmaceutical quality control of the investigational polymer-conjugated platinum anticancer agent AP 5280.

J. Beijnen, J. Rice, J. Reedijk, 2003, PDA journal of pharmaceutical science and technology.

Pharmaceutical Development of a Parenteral Lyophilized Formulation of the Investigational Polymer-Conjugated Platinum Anticancer Agent AP 5280

J. Beijnen, J. Rice, H. Talsma, 2003, Drug development and industrial pharmacy.

A kinetic study of the chemical stability of the antimetastatic ruthenium complex NAMI-A.

J. Beijnen, G. Sava, B. Nuijen, 2002, International journal of pharmaceutics.

Pharmaceutical development of anticancer agents derived from marine sources

J. Schellens, J. Beijnen, J. Jimeno, 2000, Anti-cancer drugs.

Photostability profiles of the experimental antimetastatic ruthenium complex NAMI-A.

J. Beijnen, G. Sava, B. Nuijen, 2002, Journal of pharmaceutical and biomedical analysis.

Development of a LC method for pharmaceutical quality control of the antimetastatic ruthenium complex NAMI-A.

Auke Bult, Jos H Beijnen, J. Beijnen, 2003, Journal of pharmaceutical and biomedical analysis.

Pharmaceutical development of the novel metal-based anticancer agents NAMI-A and AP 5280

M. Bouma, 2002 .

Progress in the Development of Alternative Pharmaceutical Formulations of Taxanes

J. Schellens, J. Beijnen, B. Nuijen, 2001, Investigational New Drugs.

Compatibility and stability of aplidine, a novel marine-derived depsipeptide antitumor agent, in infusion devices, and its hemolytic and precipitation potential upon i.v. administration.

J. Beijnen, B. Nuijen, A. Bult, 1999, Anti-cancer drugs.

Pharmaceutical development of a parenteral lyophilized formulation of the antimetastatic ruthenium complex NAMI-A.

J. Beijnen, H. Talsma, G. Sava, 2002, International journal of pharmaceutics.

Pharmaceutical development of a parenteral lyophilized formulation of the novel antitumor agent aplidine.

A. Heck, J. Beijnen, H. Talsma, 2000, PDA journal of pharmaceutical science and technology.

DEVELOPMENT OF AN HPLC METHOD WITH UV DETECTION FOR THE PHARMACEUTICAL QUALITY CONTROL OF THE NOVEL MARINE ANTICANCER AGENT KAHALALIDE F

H. Rosing, J. Beijnen, E. Stokvis, 2001 .

HPLC-UV METHOD DEVELOPMENT AND IMPURITY PROFILING OF THE MARINE ANTICANCER AGENT APLIDINE IN RAW DRUG SUBSTANCE AND PHARMACEUTICAL DOSAGE FORM

J. Beijnen, B. Nuijen, A. Bult, 2001 .

Development of a Lyophilized Parenteral Pharmaceutical Formulation of the Investigational Polypeptide Marine Anticancer Agent Kahalalide F

J. Beijnen, H. Talsma, J. Jimeno, 2001, Drug development and industrial pharmacy.

In vitro biocompatibility studies with the experimental anticancer agent BIBX1382BS.

J. Beijnen, U. Brauns, B. Nuijen, 2000, International journal of pharmaceutics.

The role of afferents to the ventral tegmental area in the handling stress-induced increase in the release of dopamine in the medial prefrontal cortex: a dual-probe microdialysis study in the rat brain

B. Westerink, P. Enrico, M. Bouma, 1998, Brain Research.

In vitro hemolysis and buffer capacity studies with the novel marine anticancer agent kahalalide F and its reconstitution vehicle cremophor EL/ethanol.

J. Beijnen, J. Jimeno, B. Nuijen, 2001, PDA journal of pharmaceutical science and technology.

Stability and compatibility of the investigational antimetastatic ruthenium complex NAMI-A in infusion systems and its hemolytic potential

J. Beijnen, G. Sava, B. Nuijen, 2004 .